Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 1998

View Archived Issues

Antipsoriatic dihydrofolate reductase inhibitors available for licensing from BTG

Long-term use of salmeterol for exercise-induced asthma results in decreased duration of action

Hokuriku designs potent, orally active, metabolically stable TxA2/CysLT1 antagonists

Erythromycins from Taisho for Gram-positive infections

Morinaga Milk develops peptides with antifungal activity

Benzodiazepine omega3 receptor ligands with anxiolytic, anticonvulsant and antiarthritic effects

Mer-WF-1726: new antitumor substance isolated from natural source

Spotlight on sigma-receptors as a target for intervention in CNS disorders

Cell Therapeutics licenses rights to PG-TXL

Icos begins phase II multiple-dose trial in multiple sclerosis patients

Kos files European marketing application for Niaspan and begins clinical trials with Nicostatin

Analgesic effects of dosulepin in patients with cancer-related pain

GV-150013 has dual therapeutic potential in treating alcoholism and sleep disorders

Vigabatrin is effective for treating alcohol withdrawal syndrome

Preclinical results point to anxiolytic efficacy for Yoshitomi benzodiazepine

SomatoKine progresses to phase II for a new disease indication

Lisofylline development timetable readjusted, marketing agreements revised

Scientists report success in achieving tolerance in transplantation models

L-054264, the first small-molecule sst2 receptor agonist reported

Inhibitors of iNOS described by Ono scientists

FDA clears SSRI for depression

Oncologic Drugs Advisory Committee meets for three days in September

Patient dosing begins in phase Ib trial of stroke drug from NPS

Roche to sell participation in DePuy

Neurogen's epilepsy compound advances through clinical trials

Sepracor and Janssen sign licensing agreement for cisapride metabolite

French and Israeli researchers synthesize peptides active against slow-growing, anaerobic bacteria

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...